摘要
目的探讨瑞舒伐他汀联合依达拉奉治疗急性脑梗死(ACI)的临床疗效。方法采用随机数字表法将92例ACI患者分为研究组和对照组,各46例。对照组患者采用常规降压、抗凝、防止脑水肿、改善微循环及依达拉奉治疗,研究组在对照组基础上加用瑞舒伐他汀,比较两组患者治疗后血脂、血清基质金属蛋白酶(MMP-9)、超敏C反应蛋白(hs-CRP)、颈内动脉中膜厚度(IMT)、美国国立卫生院神经功能缺损评分(NIHSS)差异。结果治疗后两组患者的hs-CRP和MMP-9较治疗前均显著降低(P<0.05),研究组下降更显著(P<0.05);治疗后,研究组的血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、IMT及NIHSS评分均较对照组显著下降(P<0.05);研究组的基本治愈率高于对照组,疗效分布显著优于对照组(P<0.05);研究组的总有效率为93.47%,高于对照组的84.78%,但差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合依达拉奉治疗ACI较单用依达拉奉能更显著地降低血脂、hs-CRP及MMP-9水平、IMT厚度,有利于提高疗效。
Objective To investigate the clinical effect of rosuvastatin combined with edaravone in treating acute cerebral infarction（ ACI）.Methods 92 patients with ACI were divided into the study group and the control group by adopting the random number table method,46 cases in each group. The control group adopted the conventional reducing pressure,anticoagulation,prevention of brain edema,improving microcirculation and edaravone treatment,while on this basis,the study group was added with rosuvastatin. The differences in blood lipids,matrix metalloproteinase- 9（ MMP- 9）,high sensitive C reactive protein（ hs- CRP）,carotid artery intima- media thickness（ IMT） and neural function defect scores of the American National Institutes of Health（ NIHSS） after treatment were compared between the two groups. Results The hs- CRP and MMP- 9 levels after treatment in the two groups were significantly decreased compared with those before treatment（ P〈 0. 05）,but the decrease in the study group was more significant than the control group（ P〈 0. 05）;TG,TC,HDL- C,LDL- C,IMT and NIHSS scores after treatment in the study group were significantly decreased compared with the control group（ P〈 0. 05）; the basic cure rate in the study group was higher than that in the control group,but no efficiency was lower than that in the control group,moreover the curative effect distribution in the study group was significantly better than that in the control group（ P〈 0. 05）; the total effect rate in the study group was 93. 47%,which was higher than 84. 78% in the control group,but the difference was not statistically significant（ P〉 0. 05）. Conclusion Rosuvastatin combined with edaravone can more significantly reduce the blood lipid,hs- CRP,MMP- 9 levels and IMT in the patients with ACI than use edaravone alone,which conduces to improue the clinical efficacy.
出处
《中国药业》
CAS
2015年第4期27-29,共3页
China Pharmaceuticals
